LONDON--(BUSINESS WIRE)--With no available therapy for the treatment of fibromyalgia syndrome (FS), pharmaceutical companies have shown great interested in coming up with possible recommendations and therapies for treatment. Central nervous system (CNS) niche disorders have always been a major challenge and FS is no different. Some of the key products in late-stage clinical trials have shown considerable promise and offer high growth opportunities.
